Researchers Develop Better Way to Determine Safe Drug Doses for Children

Determining safe yet effective drug dosages for children is an ongoing challenge for pharmaceutical companies and medical doctors alike. A new drug is usually first tested on adults, and results from these trials are used to select doses for pediatric trials. The underlying assumption is typically that children are like adults, just smaller, which often holds true, but may also overlook differences that arise from the fact that children's organs are still developing.

Compounding the problem, pediatric trials don't always shed light on other differences that can affect recommendations for drug doses. There are many factors that limit children's participation in drug trials - for instance, some diseases simply are rarer in children - and consequently, the generated datasets tend to be very sparse.

To make drugs and their development safer for children, researchers at Aalto University and the pharmaceutical company Novartis have developed a method that makes better use of available data.

"This is a method that could help determine safe drug doses more quickly and with less observations than before," says co-author Aki Vehtari, an associate professor of computer science at Aalto University and the Finnish Center for Artificial Intelligence FCAI.

In their study, the research team created a model that improves our understanding of how organs develop.

"The size of an organ is not necessarily the only thing that affects its performance. Kids' organs are simply not as efficient as those of adults. In drug modeling, if we assume that size is the only thing that matters, we might end up giving too large of doses," explains Eero Siivola, first author of the study and doctoral student at Aalto University.

Whereas the standard approach of assessing pediatric data relies on subjective evaluations of model diagnostics, the new approach, based on Gaussian process regression, is more data-driven and consequently less prone to bias. It is also better at handling small sample sizes as uncertainties are accounted for.

The research comes out of FCAI's research programme on Agile and probabilistic AI, offering a great example of a method that makes the best out of even very scarce datasets.

In the study, the researchers demonstrate their approach by re-analyzing a pediatric trial investigating Everolimus, a drug used to prevent the rejection of organ transplants. But the possible benefits of their method are far reaching.

"It works for any drug whose concentration we want to examine," Vehtari says, like allergy and pain medication.

The approach could be particularly useful for situations where a new drug is tested on a completely new group - of children or adults - which is small in size, potentially making the trial phase much more efficient than it currently is. Another promising application relates to extending use of an existing drug to other symptoms or diseases; the method could support this process more effectively than current practices.

Siivola E, Weber S, Vehtari A.
Qualifying drug dosing regimens in pediatrics using Gaussian processes.
Stat Med. 2021 May 10;40(10):2355-2372. doi: 10.1002/sim.8907

Most Popular Now

Using AI for Early Detection and Treatme…

Artificial intelligence (AI) will fundamentally change medicine and healthcare: Diagnostic patient data, e.g. from ECG, EEG or X-ray images, can be analyzed with the help of machine learning, so that...

Waiting Times for Medical Admissions Red…

Clinicians at Bolton NHS Foundation Trust have dramatically reduced patient waiting times, decreased hospital length of stay and improved patient safety after developing an electronic acute medical list solution to manage patient referrals.  The configuration was initially set-up to track referrals and admissions...

AI Algorithm Solves Structural Biology C…

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend millions of dollars to determine...

Accenture HealthTech Innovation Challeng…

Accenture (NYSE: ACN) has named eight companies as finalists in the Accenture HealthTech Innovation Challenge, which brings together leading-edge startups with prominent health companies to tackle some of North America's...

Researchers Use AI to Predict which COVI…

Researchers at Case Western Reserve University have developed an online tool to help medical staff quickly determine which COVID-19 patients will need help breathing with a ventilator. The tool, developed through...

Clinerion Patent for Technology Underpin…

The new Clinerion patent underpins any medical EHR database infrastructure that incorporates a hybrid model of cloud-and-local server node installations at individual hospitals, as well as any method for search...

Data MATRIX Introduces an AI-Operated Pa…

Data MATRIX, a sole Real-World Evidence solutions provider in Russia, has presented a predictive analytics tool for estimating patient survival based on Real-World Data. An important feature of the presented tool for...

Bittium Expands Its Minority Holdings in…

Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, and British ECG service provider, Technomed Limited, have today signed an agreement under which Bittium will purchase a 25 percent stake in...

A Game Changer: Virtual Reality Reduces …

It isn’t a matter of one needle puncture. Many children coming through the doors of Children's Hospital Los Angeles are seen for chronic conditions and often require frequent visits. Painful...

Scientists Develop AI to Predict the Suc…

A study in which machine-learning models were trained to assess over 1 million companies has shown that artificial intelligence (AI) can accurately determine whether a startup firm will fail or...

Open Call HORIZON-HLTH-2022-IND-13-04: S…

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 "Maintaining an innovative, sustainable and globally competitive health industry". To...

Ranking Apps on Privacy

The last thing you want to do when installing a new, free app on your phone is to scroll through pages of information on what kind of access to your...